Our website uses cookies to make navigation as functional as possible. Our cookies do not enable us to identify you in any way. Should you wish to receive more information, or deny your consent to all or some of the cookies, please click here to disable them. By continuing to browse this site , you will be accepting our cookies.

News

Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinosi...
The Board of Directors has appointed Mrs.  Elcin Barker Ergun   as CEO of Menarini Group.
Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-D...
Third year of ‘Get Breathless for COPD’ cycle event raise over €11k for charity Cycling along Dublin’s scenic coast, participants of the third ‘Get ...
READ ALL NEWS »
23 Sep 2019

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm



Pomezia (Italy) September 23rd, 2019 – Promising results from the preclinical study conducted by Menarini Ricerche on MEN1611, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development for the treatment of breast cancer. The poster entitled Characterization of the mechanism of action and efficacy of MEN1611, a novel PI3K inhibitor, in breast cancer preclinical models” will be presented at the ESMO Annual Meeting 2019, which will take place in Barcelona on September 27th, during the poster display session scheduled on September 30th (time 12-13).

 

The PI3K/AKT signaling pathway is often dysregulated in patients with cancer: about 25% of HER2-positive breast cancers carry PIK3CA gene mutations, known to confer resistance to anti-HER2 therapy (i.e. trastuzumab). This study, conducted in several HER2-positive PIK3CA-mutated breast cancer cell lines and patient-derived xenograft models, shows that MEN1611 is able to down-modulate the PI3K/AKT pathway both in vitro and in vivo, and acts synergistically when combined with trastuzumab; moreover, the in vivo efficacy in trastuzumab-resistant models is demonstrated by a long lasting antitumor activity.

These promising preclinical data, provide a strong rationale for MEN 1611 progression in clinical development in breast cancer patients.  In this regard, the B-Precise-01 clinical trial (NCT03767335), a multicentre phase Ib study, is currently ongoing in Europe with the aim to evaluate the preliminary clinical activity of MEN1611 in combination with trastuzumab +/- fulvestrant, in patients affected by advanced or metastatic HER2-positive breast cancer, and to select the recommended phase 2 dose

This year Menarini Ricerche will be present at ESMO congress also with a dedicated area at the MenariniSilicon Biosystems booth, where it will be possible to get more detailed information about the entire Menarini oncology pipeline and the ongoing clinical trials. Indeed, MEN1611 is part of an innovative pipeline of investigational new drugs focused on precision medicine approaches, that represents the strong and growing commitment of Menarini to oncology and to patients affected by difficult to treat cancers.

 

 

Quality first


Quality: point of departure and arrival for our drugs.

READ MORE »

Menarini in the world

The Menarini Group has companies located almost all over the world.

READ MORE »

Innovation & Research

Constant commitment to new drug research.

READ MORE »

Our values

 

10 core values have influenced the progress of our group.

READ MORE »